<?xml version="1.0" encoding="UTF-8"?>
<p id="Par2">Although there are lacking drugs evident for treating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), scientists remain attempting to identify those with therapeutic potential [
 <xref ref-type="bibr" rid="CR1">1</xref>]. Among the worldwide emerging clinical trials, Solidarity is an international clinical trial searching for an effective Coronavirus disease 2019 (COVID-19) treatment launched by the World Health Organization and its partners [
 <xref ref-type="bibr" rid="CR2">2</xref>, 
 <xref ref-type="bibr" rid="CR3">3</xref>]. The trial intends to rapidly evaluate the potential efficacy of thousands of existing antiviral and anti-inflammatory agents that are not yet approved for treating COVID-19, a process called “repurposing” or “repositioning” [
 <xref ref-type="bibr" rid="CR2">2</xref>]. Notably, in case reports, hydroxychloroquine (HCQ) has been regarded as an effective regimen reducing the copy number of SARS-CoV-2 [
 <xref ref-type="bibr" rid="CR4">4</xref>, 
 <xref ref-type="bibr" rid="CR5">5</xref>], but HCQ is also known for its cardiotoxicity [
 <xref ref-type="bibr" rid="CR6">6</xref>–
 <xref ref-type="bibr" rid="CR8">8</xref>]. In this article, we summarize the updated drugs that are currently regarded as potential anti-SARS-CoV-2 regimens and the documented cardiovascular risks.
</p>
